Dyne Therapeutics falls on revised timelines for genetic disorder therapy

Dyne Therapeutics

17/06/2025 14:52

** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20

** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA

** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting

** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo

     ** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously

     ** Also pushes submission seeking accelerated approval to late 2026 from H1 2026

** Stock down ~47% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))